Britain and America have secured a landmark bilateral deal that will keep no tariffs on British pharmaceutical exports going into the American market.
Agreement Details of the Pact
As part of the deal, the UK has committed to boost spending on pharmaceuticals through the public health system. This move guarantees that duties on these key exports will remain at zero for a timeframe of 36 months.
This agreement follows recent statements to hike duties on patented drug imports, with figures mentioned as high as double the cost.
"This agreement with the UK strengthens the international landscape for new treatments and establishes much-needed fairness to U.S.–U.K. pharmaceutical trade," a release said.
Trade Impact
Drugs represent one of the Britain's most significant goods shipped to the United States, which is easily the largest destination for major British pharmaceutical firms.
Export figures indicate that in the one-year period leading up to last September, the UK exported drugs valued at over eleven billion pounds to the US. This value made up a significant portion of all goods exports in that period.
"This deal safeguards employment, increases investment and facilitates the UK to emerge as a worldwide center for biotech and pharma," a minister remarked.
Specific NHS Changes
The pact includes several specific changes from the British government:
- Higher Cost Ceiling: The UK will increase the cost ceiling at which it considers new medicines to be too expensive by a quarter.
- Higher Drug Budget: There is a aim to increase total NHS spending on medicines from 0.3 percent of the national economy to 0.6% over the next decade.
- Rebate Cap: The percentage pharmaceutical firms must pay back to the NHS to prevent overspending will be restricted at fifteen percent. In the past, rebates were more than 20%.
Broader Context
The pact takes place against a long-running row between the sector and the ministers over drug pricing and NHS adoption.
These tensions were heightened by arguments that American patients were charged a premium for the equivalent treatments than people in the UK and Europe.
Over the last 18 months, several significant pharmaceutical investments in the UK have been delayed or abandoned, while substantial expansions have been announced toward American operations.
One official stated that the NHS had to spend more on drugs, noting that its expenditure on drugs had shrunk as a share of its resources over the previous ten-year period.
